### Monday, 31 May 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Exhibit Hall Opens</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Visit the Exhibition Hall and ePosters (Quick Pitch Sessions in round table rooms)</td>
</tr>
<tr>
<td>13:00 -13:15</td>
<td>Welcome by the Congress President – Bjarne Winther Kristensen, Copenhagen, Denmark</td>
</tr>
<tr>
<td>13:15-14:00</td>
<td><strong>Plenary Lecture 1</strong></td>
</tr>
<tr>
<td>13:15</td>
<td>Chair: Bjarne Winther Kristensen, Copenhagen, Denmark (3 min)</td>
</tr>
<tr>
<td>13:15</td>
<td><strong>Brain tumor diagnosis in transition - from single parameter analyses to multiomics</strong></td>
</tr>
<tr>
<td>13:15</td>
<td>Andreas von Deimling, Heidelberg, Germany</td>
</tr>
<tr>
<td>13:15</td>
<td>(30+12)</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td><strong>Symposium 1: Cerebrovascular diseases</strong></td>
</tr>
<tr>
<td>14:05</td>
<td>Chair: Raj Kalaria, Newcastle, UK and Kate Lykke Lambertsen, Odense, Denmark (5 min)</td>
</tr>
<tr>
<td>14:05</td>
<td><strong>S1.1 Post-stroke inflammation – target or tool for therapy</strong></td>
</tr>
<tr>
<td>14:05</td>
<td>Kate Lykke Lambertsen, Odense, Denmark</td>
</tr>
<tr>
<td>14:05</td>
<td>(18+5)</td>
</tr>
<tr>
<td>14:28</td>
<td><strong>S1.2 White matter in familial small vessel diseases: CADASIL</strong></td>
</tr>
<tr>
<td>14:28</td>
<td>Anne Joutel, Paris, France</td>
</tr>
<tr>
<td>14:28</td>
<td>(18+5)</td>
</tr>
<tr>
<td>14:51</td>
<td><strong>S1.3 White matter disease – small vessel pathology and more</strong></td>
</tr>
<tr>
<td>14:51</td>
<td>Elisabet Englund, Lund, Sweden</td>
</tr>
<tr>
<td>14:51</td>
<td>(18+5)</td>
</tr>
<tr>
<td>15:13</td>
<td><strong>S1.4 (P207) Regional proteomic mapping of the human vanishing white matter brain</strong></td>
</tr>
<tr>
<td>15:13</td>
<td>Jodie Man, Utrecht, the Netherlands</td>
</tr>
<tr>
<td>15:13</td>
<td>(5+3)</td>
</tr>
<tr>
<td>15:22</td>
<td><strong>S1.5 (P210) Volume and cell number of the hippocampus in depression, schizophrenia, and suicide subjects</strong></td>
</tr>
<tr>
<td>15:22</td>
<td>Karl-Anton Dorph-Petersen, Aarhus, Denmark</td>
</tr>
<tr>
<td>15:22</td>
<td>(5+3)</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td><strong>Symposium 2: Genetics of neurodegeneration</strong></td>
</tr>
<tr>
<td>14:05</td>
<td>Chair: Irina Alafuzoff, Uppsala, Sweden, and Colin Smith, Edinburgh, Scotland (5 min)</td>
</tr>
<tr>
<td>14:05</td>
<td><strong>S2.1 Clues to the aetiology of neurodegenerative diseases from genomic analysis</strong></td>
</tr>
<tr>
<td>14:05</td>
<td>John Hardy, London, UK</td>
</tr>
<tr>
<td>14:05</td>
<td>(18+5)</td>
</tr>
<tr>
<td>14:28</td>
<td><strong>S2.2 Pathology of genetic and sporadic Parkinson's disease</strong></td>
</tr>
<tr>
<td>14:28</td>
<td>Steve Gentleman, London, UK</td>
</tr>
<tr>
<td>14:28</td>
<td>(18+5)</td>
</tr>
<tr>
<td>14:51</td>
<td><strong>S2.3 Genetics of MND/ALS - from genes to translational approaches</strong></td>
</tr>
<tr>
<td>14:51</td>
<td>Pam Shaw, Sheffield, UK</td>
</tr>
<tr>
<td>14:51</td>
<td>(18+5)</td>
</tr>
<tr>
<td>15:14</td>
<td>Panel Discussion (15)</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td><strong>Symposium 3. CNS tumor precision oncology – what is important in the neuropathological setting</strong></td>
</tr>
<tr>
<td>14:05</td>
<td>Chair: Werner Paulus, Münster, Germany and Christine Haberler, Vienna, Austria (5 min)</td>
</tr>
<tr>
<td>14:05</td>
<td><strong>S3.1 The laboratory setup needed for CNS tumor precision oncology</strong></td>
</tr>
<tr>
<td>14:05</td>
<td>Felix Sahm, Heidelberg, Germany</td>
</tr>
<tr>
<td>14:05</td>
<td>(15+5)</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>S3.2. Experience and results from a precision oncology phase I unit</strong></td>
</tr>
<tr>
<td>14:25</td>
<td>Ulrik Lassen, Copenhagen, Denmark</td>
</tr>
<tr>
<td>14:25</td>
<td>(15+5)</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>S3.3 Molecular diagnostics of brain tumors - current practice and the next frontiers</strong></td>
</tr>
<tr>
<td>14:45</td>
<td>Sebastian Brandner, London, United Kingdom</td>
</tr>
<tr>
<td>14:45</td>
<td>(15+5)</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>S3.4 (P129) Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma</strong></td>
</tr>
<tr>
<td>15:05</td>
<td>Christian Mirian, Copenhagen/Geneva, Denmark/Switzerland</td>
</tr>
<tr>
<td>15:05</td>
<td>(5+3)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>15:13</td>
<td><strong>S3.5 (P123)</strong> Diffuse midline glioma, H3 K27M-mutant (DMG,H3) with BRAF V600E mutation. Presentation of two cases treated with BRAF V600 inhibitors (5+3) Mónica Mezmezian, Buenos Aires, Argentina</td>
</tr>
<tr>
<td>15:21</td>
<td><strong>S3.6 (P194)</strong> Nanocarrier using protoporphyrin IX-loaded albumin nanoemulsion for image-guided glioblastoma therapies (5+3) Luciano Neder, Ribeirao Preto, Brazil</td>
</tr>
<tr>
<td>15:30-15:45</td>
<td><strong>BREAK.</strong> Please visit the Exhibition Hall and ePosters</td>
</tr>
</tbody>
</table>
| 15:45-17:15 | **Workshop 1. Primary Tauopathies**  
|           | Chairs: Gabor Kovacs, Toronto, Canada and Dennis Dickson, Jacksonville, Florida, USA |
| 15:50    | **W1.1 Overview of tau pathologies: Interactive slide session using scanned slides** (20+5) Gabor Kovacs, Toronto, Canada |
| 16:15    | **W1.2 Tau pathology related to brain trauma** (20+5)  
|           | Colin Smith, Edinburgh, Scotland |
| 16:40    | **W1.3 Deconvolving the individual contributions of comorbid tau neuropathologies using deep learning** (5+3)  
|           | Anthony Vega, Dallas, Texas, USA |
| 16:48    | **W1.4 Aggregates of RNA binding proteins and ER chaperones linked to exosomes in granulovacuolar degeneration of the Alzheimer’s disease brain** (5+3)  
|           | Alfred Yamoah, Aachen, Germany |
| 16:56    | **W1.5 Tau related changes in post mortem retina in Alzheimer’s disease and other tauopathies** (5+3)  
|           | Jeroen Hoozemans, Amsterdam, the Netherlands |
| 17:04    | **Panel Discussion** (11) |
| 15:45-17:15 | **Workshop 2. Muscle biopsy and molecular biology: a successful cooperation**  
|           | Chairs: Lammens, Antwerpen, Belgium and Werner Stenzel, Berlin, Germany (5 min) |
| 15:49    | **W2.1 Interactive case discussions** (8+5)  
|           | Eleonora Aronica, Amsterdam, the Netherlands |
| 16:02    | **W2.2 Interactive case discussions** (8+5)  
|           | Joachim Weis, Aachen, Germany |
| 16:15    | **W2.3 Interactive case discussions** (8+5)  
|           | Willem de Ridder, Antwerp, Belgium |
| 16:28    | **W2.4 Interactive case discussions** (8+5)  
|           | Eleonora Aronica, Amsterdam, the Netherlands |
| 16:41    | **W2.5 Interactive case discussions** (8+5)  
|           | Wilfred den Dunnen, Groningen, the Netherlands |
| 16:54    | **W2.6 Interactive case discussions** (8+5)  
|           | Werner Stenzel, Berlin, Germany |
| 17:07    | **W2.7 Automated large-scale scanning transmission electron microscopy of myopathies with structural abnormalities** (5+3)  
|           | Carsten Dittmayer, Berlin, Germany |
| 15:45-17:15 | **Workshop 3. Pituitary and sellar lesions**  
|           | Chairs: Olivera Casar-Borota, Uppsala, Sweden and Henning Boldt, Odense, Denmark (5 min) |
| 15:50    | **W3.1 The 2017 WHO classification of pituitary neuroendocrine neoplasms. What have we learnt?** (14+3)  
|           | Olivera Casar-Borota, Uppsala, Sweden |
| 16:07    | **W3.2 Morphology meets genomics and epigenomics: should we move towards an integrated tissue diagnosis of PitNETs** (14+3)  
|           | Olaf Anzorge, Oxford, UK |
| 16:24    | **W3.3 Molecular pathways and targets in pituitary tumors** (14+3)  
<p>|           | Marily Theodoropoulou, Munich, Germany |
| 16:41    | <strong>W3.4 Pituitary lesions from an endocrinologist’s perspective</strong> (14+3) |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:58</td>
<td>W3.5 Interactive slide-based case presentations (14+3)</td>
<td>Olaf Ansorge, Oxford, UK</td>
</tr>
<tr>
<td>17:15</td>
<td><strong>BREAK. Please visit the Exhibition Hall and ePosters</strong></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td><strong>Plenary Lecture 2</strong></td>
<td></td>
</tr>
<tr>
<td>17:30-18:15</td>
<td>Chair: Paul Ince, Sheffield, UK (3 min)</td>
<td></td>
</tr>
<tr>
<td>17:30-18:15</td>
<td>Lessons learned from brain banking for neurodegenerative diseases (30+12)</td>
<td>Dennis Dickson, Jacksonville, FL, USA</td>
</tr>
<tr>
<td></td>
<td>(Lecture supported by BNS and NAN)</td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday, 1 June 2021</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Visit the Exhibition Hall and ePosters (Quick Pitch Sessions in round table rooms)</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td><strong>Plenary Lecture 3</strong></td>
<td></td>
</tr>
<tr>
<td>13:00-13:45</td>
<td>Chair: Eleonora Aronica, Amsterdam, the Netherlands (3 min)</td>
<td></td>
</tr>
<tr>
<td>13:00-13:45</td>
<td>Brain somatic mutations in focal cortical dysplasias (30+12)</td>
<td>Stéphanie Baulac, Paris, France</td>
</tr>
<tr>
<td>13:45-14:00</td>
<td><strong>BREAK. Please visit the Exhibition Hall and ePosters</strong></td>
<td></td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>Symposium 4. The 2021 WHO CNS tumor classification: The Fifth!</td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>S4.1 From cIMPACT-NOW to WHO 2021 classification of CNS tumors (16+4)</td>
<td>Pieter Wesseling, Amsterdam/Utrecht, the Netherlands</td>
</tr>
<tr>
<td>14:25</td>
<td>S4.2 The WHO 2021 classification of diffuse gliomas (adult &amp; pediatric) (16+4)</td>
<td>Guido Reifenberger, Düsseldorf, Germany</td>
</tr>
<tr>
<td>14:45</td>
<td>S4.3 The WHO 2021 classification of circumscribed gliomas and glioneuronal tumors (16+4)</td>
<td>Dominique Figarella-Branger, Marseille, France</td>
</tr>
<tr>
<td>15:05</td>
<td>S4.4 (25) Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>Symposium 5. Mechanisms of brain inflammation</td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>S5.1 Pathways of drainage of interstitial and cerebrospinal fluids from the brain. Significance for neurological diseases (20+3)</td>
<td>Roxana Carare, Southampton, UK</td>
</tr>
<tr>
<td>14:28</td>
<td>S5.2 Immune cell interaction with the blood-brain barrier in the pathogenesis of inflammation (20+3)</td>
<td>Britta Engelhardt, Bern, Switzerland</td>
</tr>
<tr>
<td>14:51</td>
<td>S5.3 Pathology of different human inflammatory CNS diseases – an expanding spectrum (20+3)</td>
<td>Hans Lassmann, Vienna, Austria</td>
</tr>
<tr>
<td>15:14</td>
<td>S5.4 Panel discussion (15 min)</td>
<td></td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>Symposium 6. Immuno-oncology</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>Chairs: Anna Berghof, Vienna, Austria and Bjarne Kristensen, Odense, Denmark</td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>S6.1 The inflammatory microenvironment as a therapeutic target in glioma (16+4)</td>
<td>Anna Berghof, Vienna, Austria</td>
</tr>
<tr>
<td>14:25</td>
<td>S6.2 Genetic changes and T-cell infiltration in gliomas (16+4)</td>
<td>Pim French, Amsterdam, the Netherlands</td>
</tr>
<tr>
<td>14:45</td>
<td>S6.3 Understanding and targeting the microenvironment in IDH-mutant gliomas (16+4)</td>
<td>Lukas Bunse, Mannheim, Germany</td>
</tr>
<tr>
<td>15:05</td>
<td>S6.4 (P111) Single-cell analysis of tumor-associated microglia and macrophages from human glioblastoma (5+3)</td>
<td></td>
</tr>
</tbody>
</table>
| 15:13 | **S6.5 (P115)** Deconvolution of immunotherapy-treated glioblastoma identifies cellular heterogeneity and plasticity at the single-cell level (5+3)  
Josephine Deleuran Hendriksen, Copenhagen, Denmark |
| 15:21 | **S6.6 (P135)** Defects of mismatch repair proteins in pediatric high grade gliomas (5+3)  
Christine Haberler, Vienna, Austria |

---

**15:30-15:45 – BREAK.** Please visit the Exhibition Hall and ePosters

---

**15:45-17:15 – Workshop 4. Slide seminar on human prion diseases: histotyping and identification of atypical phenotypes**

| 15:45 | Chairs: Ellen Gelpi, Vienna, Austria, and Piero Parchi, Bologna, Italy |
| 15:50 | **W4.1 Interactive histotyping of CJD subtypes including genetic and atypical forms** (85 minutes total)  
Ellen Gelpi and Piero Parchi Gelpi and Parchi |

---

**15:45-17:15 – Workshop 5. Case discussions of CNS tumors with multi-layered information**

| 15:45 | Chairs: Felix Sahm, Heidelberg, Germany, and David Capper, Berlin, Germany |
| 15:50 | **W5.1. Practical NGS evaluation** (20+8)  
Felix Sahm, Heidelberg, Germany |
| 16:18 | **W5.2. Practical DNA methylation evaluation** (20+8)  
David Capper, Berlin, Germany |
| 16:46 | **W5.3. Interactive case discussions** (28)  
Felix & David Sahm & Capper |

---

**15:45-17:15 – Workshop 6. Developmental neuropathology: recent advances and future challenges**

| 15:45 | Chairs: Eleonora Aronica, Amsterdam, the Netherlands, and Karen Bonde Larsen, Copenhagen, Denmark |
| 15:50 | **W6.1 The value of postmortem examination in neurodevelopmental diseases** (15+5)  
Homa Adle-Biassette, Paris, France |
| 16:10 | **W6.2. Interneurons in cerebral cortical developmental disorders** (15+5)  
Jeffrey Golden, Boston, USA |
| 16:30 | **W6.3 Neuropathology of focal cortical dysplasias: 2021 update** (15+5)  
Ingmar Blümcke, Erlangen, Germany |
| 16:50 | **W6.4 Panel Discussion** (25) |

**17:15-17:30 – BREAK.** Please visit the Exhibition Hall and ePosters

---

**17:30-18:30 FREE COMMUNICATIONS I-II-III**

---

**Wednesday, 2 June 2021**

12:00-13:00 - Visit the Exhibition Hall and ePosters (Quick Pitch Sessions in round table rooms)

---

**13:00-13:45 – Plenary Lecture 4**

| 13:00 | Chair: David Scheie, Copenhagen, Denmark (3 min)  
The invasive behavior of glioma cells in the CNS and their biological characteristics (30+12)  
Rolf Bjerkvig, Bergen, Norway |
| 13:45-14:00 | Break. Please visit the Exhibition Hall and ePosters

---

**14:00-15:30 - Symposium 7. TDP-43 proteinopathies**

| 14:00 | Chairs: Manuela Neumann, Tübingen, Germany, and Olaf Ansorge, Oxford, UK (5) |
| 14:05 | **S7.1 Neuropathology of FTLD-TDP** (25+5)  
Ian Mackenzie, Vancouver, Canada |
| 14:35 | **S7.2 Cellular and system vulnerability in ALS** (25+5)  
Olaf Ansorge, Oxford, UK |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:05 | **S7.3 (P009) Cognitive decline in amyotrophic lateral sclerosis: neuropathological substrate and genetic determinants (5+3)**  
Sergi Borrego-Écija, Barcelona, Spain |
| 15:13 | **S7.4 (P011) Neuroanatomy of FTD: whole-brain correlations between symptoms and pathologies (5+3)**  
Marta Scarioni, Amsterdam, the Netherlands |
| 15:21 | **S7.5 (P033) Defining and diagnosing neurodegenerative movement disorders through integrated analysis of genetics and neuropathology (MD-GAP) (5+3)**  
Lesley Wu, London, UK |
| 14:00-15:30 | **Symposium 8. Myositis – clinical, morphological and differential diagnostic highlights** |
| 14:00 | Chairs: Werner Stenzel, Berlin, Germany, and Anne Schänzer, Giessen, Germany |
| 14:05 | **S8.1 Clinical diagnostic aspects in myositis (18+5)**  
Olivier Benveniste, Parijs, France |
| 14:28 | **S8.2 Morphological diagnostic aspects in myositis (18+5)**  
Werner Stenzel, Berlin, Germany |
| 14:51 | **S8.3 Differential diagnostic aspects in myositis (18+5)**  
Benedikt Schoser, München, Germany |
| 15:14 | **S8.4 (P205) Differential diagnosis of vacuolar myopathies in the NGS era (5+3)**  
Joachim Weis, Aachen, Germany |
| 15:22 | **S8.5 (P199) NanoString technology distinguishes anti-TIF-1γ+ from anti-Mi-2+ dermatomyositis patients (5+3)**  
Josephine Radke, Berlin, Germany |
| 14:00-15:30 | **Symposium 9. White matter and oligodendrocyte pathology: new insights in neurodevelopmental diseases and epilepsy** |
| 14:00 | Chairs: Eleonora Aronica, Amsterdam, the Netherlands, and Karen Bonde Larsen, Copenhagen, Denmark (5 min) |
| 14:05 | **S9.1 White matter pathology in vanishing white matter: the role of astroglial pathology (16+4)**  
Marianna Bugiani, Amsterdam, the Netherlands |
| 14:25 | **S9.2 Myelin loss and oligodendrocyte pathology in tuberous sclerosis and other mTORopathies (16+4)**  
Angelika Muehlebner, Amsterdam, the Netherlands |
| 14:45 | **S9.3 White matter in temporal lobe epilepsy: clinico-pathological correlates (16+4)**  
Maria Thom, London, UK |
| 15:05 | **S9.4 (P081) Mimicking white matter pathology in a 3D-nanofiber cell culture system derived from children with drug-resistant epilepsies (5+3)**  
Victoria-Elisabeth Gruber, Vienna, Austria |
| 15:13 | **S9.5 (P082) DNA methylation-based classification of malformations of cortical development (5+3)**  
Ingmar Bluemcke, Erlangen, Germany |
| 15:21 | **S9.6 (P080) The antiseizure and antiepileptogenic effect of matrix metalloproteinase inhibitor IPR-179 and its potential mechanisms of action (5+3)**  
Diede W. Broekaart, Amsterdam, the Netherlands |
| 15:30-15:45 | Break. Please visit the Exhibition Hall and ePosters |
| 15:45-17:15 | **Workshop 7. Assessment of the contributions of mixed pathologies in the ageing brain** |
| 15:45 | Chairs: Colin Smith, Edinburgh, Scotland, and Irina Alafuzoff, Uppsala, Sweden |
| 15:50 | **W7.1 Mixed pathology in the aged demented (15+3)**  
Johannes Attems, Newcastle, UK |
| 16:08 | **W7.2 Amygdala, a hotspot of pathology in aged (15+3)**  
Irina Alafuzoff, Uppsala, Sweden |
| 16:26 | **W7.7 Interactive slide session using scanned slides (15)**  
t.b.d. |
| 16:41 | **W7.3 (P037) Unique changes in gene activity in the ventral midbrain precedes dopaminergic degeneration in Parkinson’s disease mouse models (5+3)**  
Pierre Garcia, Dudelange/Esch-sur-Alzette, Luxembourg |
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:49</td>
<td>W7.4 (P021) Subregional severity of proteinopathies in the hippocampus of late onset Alzheimer’s Disease (AD) and Dementia with Lewy Bodies (DLB) patients (5+3)</td>
<td>Sonja Fixemer, Dudelange/ Belval, Luxembourg</td>
</tr>
<tr>
<td>16:57</td>
<td>W7.5 (P026) Limbic-predominant age-related TDP-43 encephalopathy (LATE) in a cohort of patients with dementia: evidence of an early phase of hippocampal sclerosis (5+3)</td>
<td>Alicia Uceda Heras, Madrid, Spain</td>
</tr>
<tr>
<td>17:05</td>
<td>W7.6 (P022) Diabetes is associated with vascular dementia, not Alzheimer’s disease or Lewy body dementia (5+3)</td>
<td>Keivan Javanshiri, Lund, Sweden</td>
</tr>
</tbody>
</table>

**15:45-17:15 – Workshop 8. Progress in the pathological diagnosis of pediatric and adult CNS tumors**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45</td>
<td>Chairs: Pietsch, Bonn, Germany, and Dominique Figarella-Branger, Marseille, France</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>W8.2 Modern diagnostics of ependymal tumors (15+5)</td>
<td>Dominique Figarella-Branger, Marseille, France</td>
</tr>
<tr>
<td>16:30</td>
<td>W8.3 Differential diagnostics of primitive &quot;embryonal&quot; tumors (15+5)</td>
<td>Torsten Pietsch, Bonn, Germany</td>
</tr>
<tr>
<td>16:50</td>
<td>8.4. (P118) EpiDiP.org: an open access epigenomics diagnostic resource (5+3)</td>
<td>Juergen Hench, Basel, Switzerland</td>
</tr>
<tr>
<td>16:58</td>
<td>W8.5 (P102) Establishment of Droplet Digital™ PCR (ddPCR™) for rapid molecular diagnostics of brain tumors (5+3)</td>
<td>Guido Reifenberger, Düsseldorf/Heidelberg, Germany</td>
</tr>
<tr>
<td>17:06</td>
<td>W8.6 (P127) Identification of two main subgroups among posterior pituitary tumors associated with histology, MAPK/PI3K mutations, epigenetic regulator mutations, CNV and outcome (5+3)</td>
<td>Simone Schmid, Berlin, Germany</td>
</tr>
</tbody>
</table>

**15:45-17:15 – Workshop 9. B cells in inflammatory demyelinating diseases**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45</td>
<td>Chairs: Hans Lassmann, Vienna, Austria, and Trevor Owens, Odense, Denmark</td>
<td></td>
</tr>
<tr>
<td>15:50</td>
<td>W9.1 B-cell inflammation in MS (14+3)</td>
<td>Marvin van Luijn, Rotterdam, the Netherlands</td>
</tr>
<tr>
<td>16:07</td>
<td>W9.2 Roles of B-cells in MS and potential consequences for therapy (14+3)</td>
<td>Amit Bar-Or, Philadelphia, USA</td>
</tr>
<tr>
<td>16:24</td>
<td>W9.3 Antibody mediated autoimmune diseases of the nervous system (14+3)</td>
<td>Romana Höftberger, Vienna, Austria</td>
</tr>
<tr>
<td>16:41</td>
<td>W9.4 MOG encephalomyelitis and NMOSD – insights from animal models (14+3)</td>
<td>Trevor Owens, Odense, Denmark</td>
</tr>
<tr>
<td>16:58</td>
<td>W9.5 The CD20+ T cell: a wolf in sheep’s clothing? (14+3)</td>
<td>Marina von Essen, Copenhagen, Denmark</td>
</tr>
</tbody>
</table>

**17:15-17:30 – BREAK. Please visit the Exhibition Hall and ePosters**

**17:30-18:30 - FREE COMMUNICATIONS IV-V-VI**

**Thursday, 3 June**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-13:00</td>
<td>ISN Business Meeting (For ISN Council &amp; Executive Committee only (upon invitation)</td>
<td></td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Visit the Exhibition Hall and ePosters (Quick Pitch Sessions in round table rooms)</td>
<td></td>
</tr>
</tbody>
</table>

**13:00-13:45 Plenary Lecture 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Chair: Joachim Weis, Aachen, Germany (3 min)</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Polyglucosan storage in muscle and brain - disease entities and pathogenesis (30+12)</td>
<td>Berge Minassian, Dallas, USA</td>
</tr>
</tbody>
</table>

**13:45-14:00 BREAK. Please visit the Exhibition Hall and ePosters**

**14:00-15:30 Symposium 10. Neuropathology training, Courses and Examination (EFN) in Europe**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Chairs: Tibor Hortobagyi, Debrecen/Szeged, Hungary and Wilfred den Dunnen, Groningen, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>Round-table' discussion, with lecturers and participants of Euro-CNS courses, examiners and candidates of EFN examinations. Neuropathology training across Europe: the current situation and challenges of the future</td>
<td></td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>S11. Intratumoral heterogeneity</td>
<td>Chairs: Rolf Bjerkvig, Bergen, Norway, and Hrvoje Miletic, Bergen, Norway</td>
</tr>
<tr>
<td>14:05</td>
<td>S11.1 Longitudinal molecular trajectories of diffuse glioma in adults (14+3)</td>
<td>Roel Verhaak, Bar Harbor, Maine, USA</td>
</tr>
<tr>
<td>14:22</td>
<td>S11.2 Epigenomic contribution to glioblastoma heterogeneity (14+3)</td>
<td>Adelheid Woehrer, Vienna, Austria</td>
</tr>
<tr>
<td>14:39</td>
<td>S11.3 Role of intrinsic tumor plasticity and microenvironment in creating intratumoral heterogeneity in glioblastoma (14+3)</td>
<td>Anna Golebiewska, Luxembourg, Luxembourg</td>
</tr>
<tr>
<td>14:56</td>
<td>S11.4 Brain tumor invasion into the CNS - mechanisms of action (14+3)</td>
<td>Rolf Bjerkvig, Bergen, Norway</td>
</tr>
<tr>
<td>15:13</td>
<td>S11.5 (P095) Subependymoma of the posterior fossa may progress to ependymoma: Role of TERT mutation, loss of chromosome 6 and methylome alterations (5+3)</td>
<td>Christian Thomas, Münster, Germany</td>
</tr>
<tr>
<td>15:21</td>
<td>S11.6 (P128) Integrated analysis of molecular alterations and immune cell infiltration in primary and recurrent glioblastomas (5+3)</td>
<td>Jeanette Krogh Pedersen, Odense, Denmark</td>
</tr>
<tr>
<td>14:05</td>
<td>S12.1 The relationship between spreading and maturation of amyloid-β pathology in AD (15+5)</td>
<td>Dietmar Thal, Leuven, Belgium</td>
</tr>
<tr>
<td>14:25</td>
<td>S12.2 Evidence for the person to person transmissibility of amyloid-β, (15+5)</td>
<td>Zane Jaunmuktane, London, UK</td>
</tr>
<tr>
<td>14:45</td>
<td>S12.3 Removal of amyloid-β from the brain by immunotherapy (15+5)</td>
<td>James Nicoll, Southampton, UK</td>
</tr>
<tr>
<td>15:05</td>
<td>S12.4 (P017) Alzheimer’s disease neuropathological change and loss of neuropil and matrix in idiopathic normal pressure hydrocephalus, a model of Alzheimer’s disease (5+3)</td>
<td>Sylwia Libard, Uppsala, Sweden</td>
</tr>
<tr>
<td>15:13</td>
<td>S12.5 (P020) The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease (5+3)</td>
<td>Baayla Boon, Amsterdam, the Netherlands</td>
</tr>
<tr>
<td>15:21</td>
<td>S12.6 (P024) Systemic infection exacerbates cerebral hypoperfusion and blood-brain-barrier breakdown in Alzheimer’s disease and vascular dementia (5+3)</td>
<td>Daniel Asby, Bristol, UK</td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>BREAK. Please visit the Exhibition Hall and ePosters</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>S13.1 Brain pathology of COVID-19 (20+3)</td>
<td>Markus Glatzel, Hamburg, Germany</td>
</tr>
<tr>
<td>16:13</td>
<td>S13.2 COVID-19 encephalitis; the pathological evidence (20+3)</td>
<td>Safa Al-Sarraj, London, UK</td>
</tr>
<tr>
<td>16:36</td>
<td>S13.3 (P234) Olfactory transmuscoal SARS-CoV2- invasion as port of CNS entry in COVID-19 (7+3)</td>
<td>Jenny Meinhardt, Berlin, Germany</td>
</tr>
<tr>
<td>16:46</td>
<td>S13.4 (P231) Post infectious myopathy related to COVID-19 (7+3)</td>
<td>Leila Chimelli, Rio de Janeiro, Brazil</td>
</tr>
<tr>
<td>16:45</td>
<td>Panel discussion (19)</td>
<td></td>
</tr>
</tbody>
</table>
17:15-17:30 – BREAK. Please visit the Exhibition Hall and ePosters

### 17:30-18:15 Plenary Lecture 6

<table>
<thead>
<tr>
<th>Chair: Eva Løbner Lund, Copenhagen, Denmark (3 min)</th>
<th>Deciphering phenotypic variability and transmission properties of human prion diseases (30+12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piero Parchi, Bologna, Italy</td>
<td></td>
</tr>
</tbody>
</table>

18:15-18:30 Prizes and Closure